TrialArthritis & rheumatology (Hoboken, N.J.)2023

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.

Eric Morand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.